CYCN - Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $13.6M
- Beta
- 1.80
- 52-Week Range
- 1.027-8.48
- CEO
- Regina Graul
- Employees
- 1
- IPO Date
- Mar 18, 2019
- Exchange
- NASDAQ
CYCN Options Snapshot
Options pricing data for CYCN is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.
What This Page Covers
The CYCN overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked CYCN overview questions
- What is CYCN?
- CYCN is the ticker symbol for Cyclerion Therapeutics, Inc., a listed security. Cyclerion Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Listed on NASDAQ. CYCN is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What are CYCN's key statistics?
- Cyclerion Therapeutics, Inc. (CYCN) carries a market capitalization of $13.6M, beta of 1.80 relative to the broader market, 52-week range of 1.027-8.48. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does CYCN belong to?
- Cyclerion Therapeutics, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare CYCN's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the CYCN data on this page?
- Options snapshots refresh after each trading session; if no snapshot is currently posted for CYCN, it usually reflects low options liquidity or a recently listed name. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).